This Viewpoint discusses the reasons that drug manufacturing is leaving the US; highlights the weaknesses of tariffs as currently implemented for bringing it back; and calls for the moderate implementation of tariffs as one component of industrial policy and the reinvestment of tariff revenues in pharmaceutical innovation.
James C. Robinson (Mon,) studied this question.